Earnings summaries and quarterly performance for TELEFLEX.
Executive leadership at TELEFLEX.
Liam Kelly
Detailed
Chairman, President and Chief Executive Officer
CEO
DL
Daniel Logue
Detailed
Corporate Vice President, General Counsel and Secretary
JW
James Winters
Detailed
Corporate Vice President, Manufacturing and Supply Chain
JW
Jay White
Detailed
Corporate Vice President and President, Global Commercial
JD
John Deren
Detailed
Executive Vice President and Chief Financial Officer
Board of directors at TELEFLEX.
Research analysts who have asked questions during TELEFLEX earnings calls.
Jayson Bedford
Raymond James
6 questions for TFX
Also covers: AXGN, BDX, DXCM +8 more
Michael Polark
Wolfe Research
5 questions for TFX
Also covers: BBNX, BSX, DXCM +13 more
AP
Anthony Petrone
Mizuho Group
4 questions for TFX
Also covers: ADMA, ALC, AXGN +24 more
LB
Larry Biegelsen
Wells Fargo & Company
4 questions for TFX
Also covers: ABT, ALC, AXNX +25 more
SS
Shagun Singh Chadha
RBC Capital Markets
4 questions for TFX
Also covers: AXNX, BDX, DXCM +12 more
CB
Craig Bijou
Bank of America Securities
3 questions for TFX
Also covers: BLCO, COO, FNA +9 more
MO
Matthew O'Brien
Piper Sandler & Co.
3 questions for TFX
Also covers: APYX, ATEC, ATRC +18 more
Michael Matson
Needham & Company
3 questions for TFX
Also covers: AORT, ATRC, CNMD +22 more
Mike Matson
Needham & Company, LLC
3 questions for TFX
Also covers: AORT, ATRC, CNMD +19 more
Patrick Wood
Morgan Stanley
3 questions for TFX
Also covers: ALC, BDX, BLCO +20 more
RM
Ravi Misra
Truist Securities
3 questions for TFX
Also covers: GKOS, IART, KIDS
RN
Richard Newitter
Truist Securities
3 questions for TFX
Also covers: AXNX, BBNX, DXCM +19 more
Bradley Bowers
Mizuho Securities USA LLC
2 questions for TFX
Also covers: COO, MDXG, STAA +1 more
MO
Matthew O'Brien
Piper Sandler
2 questions for TFX
Also covers: BBNX, CNMD, DXCM +5 more
SS
Shagun Singh
RBC
2 questions for TFX
Also covers: GMED, INSP, TNDM
Travis Steed
Bank of America
2 questions for TFX
Also covers: ABT, AXNX, BAX +24 more
DT
David Turkaly
Citizens JMP
1 question for TFX
Also covers: AXGN, FNA, HAE +5 more
KS
Kristen Stewart
CL King & Associates
1 question for TFX
Also covers: AVNS, CNMD, HAE +3 more
MT
Matthew Taylor
Jefferies
1 question for TFX
Also covers: ALUR, BDX, BSX +21 more
MT
Matt Taylor
Jefferies & Company Inc.
1 question for TFX
Also covers: ABT, BAX, BDX +16 more
MS
Michael Sarcone
Jefferies
1 question for TFX
Also covers: ALC, ALGN, AXGN +12 more
Mike Polark
Wolfe Research, LLC
1 question for TFX
Also covers: BBNX, BSX, DXCM +6 more
VC
Vikramjeet Chopra
Wells Fargo & Company
1 question for TFX
Also covers: ALGN, ATEC, CNMD +9 more
Recent press releases and 8-K filings for TFX.
Teleflex announces Q4 2025 earnings and 2026 outlook
TFX
Earnings
Guidance Update
Share Buyback
- Teleflex reported Q4 2025 GAAP revenue of $569.0 million, adjusted operating margin of 21.5%, and adjusted EPS of $1.93.
- Full-year 2025 adjusted revenue totaled $1,983.7 million, with adjusted operating margin 22.7% and adjusted EPS $6.98.
- 2026 guidance includes GAAP revenue growth of 14.4–15.4% to $2.28–2.30 billion, pro forma adjusted constant-currency growth of 4.5–5.5%, GAAP EPS of $2.90–3.20, and adjusted EPS of $6.25–6.55.
- Strategic divestitures of Acute Care, Interventional Urology, and OEM businesses are expected to close in 2H 2026, generating $1.8 billion in after-tax proceeds to fund a $1 billion share repurchase and $800 million debt repayment post-closing.
Feb 26, 2026, 1:00 PM
Teleflex announces Q4 2025 results
TFX
Earnings
CEO Change
Guidance Update
- Stuart Randle named Interim CEO and Teleflex signed definitive agreements to divest Acute Care, Interventional Urology, and OEM businesses for $2.03 billion in cash proceeds (net $1.8 billion), with transactions expected to close in H2 2026.
- RemainCo (focused on Vascular, Interventional, and Surgical) delivered 4.7% pro forma adjusted constant currency growth in H2 2025, and the company guides to 4.5%–5.5% growth for 2026.
- In 2025, Teleflex reported a 63.7% adjusted gross margin, 22.7% adjusted operating margin, $6.98 adjusted EPS, and ended Q4 with $402.7 million in cash and restricted cash.
- 2026 adjusted EPS guidance is $6.25–$6.55, which reflects $90 million of stranded costs but excludes benefits from transition services, planned $1 billion share repurchases, and debt repayments; net interest expense is expected to be $105 million with a 13.5% tax rate.
Feb 26, 2026, 1:00 PM
Teleflex reports Q4 2025 results and strategic divestiture plans
TFX
Earnings
CEO Change
Guidance Update
- Teleflex appointed Stuart Randle as interim CEO following the announced sale of its Acute Care, Interventional Urology, and OEM businesses, with a permanent CEO search underway.
- Signed agreements to divest three non-core businesses for $2.03 billion gross proceeds (net ~$1.8 billion after tax), expected to close in H2 2026; proceeds will fund a $1 billion share repurchase and debt reduction.
- FY 2025 continuing operations delivered adjusted gross margin of 63.7%, operating margin of 22.7%, and EPS of $6.98 (up 8.7% YoY); year-end cash and equivalents were $402.7 million.
- 2026 continuing operations guidance: 4.5%–5.5% pro forma constant currency revenue growth, EPS of $6.25–$6.55, operating margin ~19%, and R&D ~8% of sales.
- Expect ~$90 million in stranded costs in 2026 to be fully offset post-close by transition and manufacturing service agreements, with a board-approved restructuring targeting $50 million in annual savings and a steady-state operating margin of ~23%.
Feb 26, 2026, 1:00 PM
Teleflex reports Q4 2025 results and strategic update
TFX
Earnings
M&A
Guidance Update
- Teleflex appointed an interim CEO in January and has engaged Spencer Stuart to lead a disciplined search for a permanent CEO, aiming to maintain momentum across its strategic priorities as it transitions to a more focused RemainCo structure.
- For full‐year 2025, adjusted gross margin was 63.7% (–200 bps YoY), adjusted operating margin was 22.7% (–230 bps YoY), adjusted EPS was $6.98 (+8.7% YoY), and year‐end cash and restricted cash totaled $402.7 million.
- Teleflex signed definitive agreements to divest its Acute Care, Interventional Urology, and OEM businesses, expected to generate $2.03 billion in gross proceeds (≈ $1.8 billion net) and close in H2 2026.
- Net divestiture proceeds will fund a $1 billion share buyback and $800 million of debt repayment, primarily against its deferred-draw revolver.
- 2026 outlook includes $6.25–$6.55 adjusted EPS, 4.5%–5.5% pro forma constant currency revenue growth, and ~19% adjusted operating margin (inclusive of ~$90 million stranded costs and 8% R&D spend).
Feb 26, 2026, 1:00 PM
Teleflex reports 2025 results and 2026 outlook
TFX
Earnings
Guidance Update
Share Buyback
- Teleflex full year 2025 continuing operations: GAAP revenue of $1,992.7 M (+17.2% YoY); adjusted revenue $1,983.7 M (+16.3% YoY, +15.4% CC); GAAP diluted EPS $1.31; adjusted diluted EPS $6.98
- 2026 guidance: GAAP revenue growth of 14.4–15.4%; pro forma adjusted constant currency growth of 4.5–5.5%; GAAP EPS $2.90–$3.20; adjusted EPS $6.25–$6.55
- Approved multi-year restructuring tied to strategic divestitures, incurring $31–37 M of charges and targeting $48–52 M of annual pre-tax savings; includes ~$90 M stranded costs to be offset by post-close TS/MS agreements
- Strategic divestitures expected to close in 2H 2026, with
$1.8 B after-tax proceeds planned for a $1 B share buyback and **$800 M** debt paydown
Feb 26, 2026, 12:00 PM
Teleflex reports 2025 results and 2026 outlook
TFX
Earnings
Guidance Update
Share Buyback
- Teleflex reported GAAP revenue from continuing operations of $1.99 billion in 2025, a 17.2% increase year-over-year; adjusted revenue was $1.98 billion, up 16.3% (15.4% constant currency).
- GAAP diluted EPS from continuing operations was $1.31, while adjusted diluted EPS was $6.98 for the full year 2025.
- For full year 2026, the company guides GAAP revenue growth of 14.4–15.4% (including ~0.7% FX), pro forma adjusted constant currency revenue growth of 4.5–5.5%, GAAP EPS of $2.90–$3.20, and adjusted EPS of $6.25–$6.55.
- Teleflex initiated a restructuring plan to eliminate $48–52 million of annual stranded costs related to strategic divestitures, expected to close in H2 2026, and plans to use net proceeds primarily for share repurchases and debt paydown.
Feb 26, 2026, 11:30 AM
Teleflex announces leadership transition and revenue outlook update
TFX
CEO Change
Board Change
Guidance Update
- Stuart Randle appointed Interim President and CEO, effective January 8, 2026, succeeding Liam Kelly.
- Dr. Stephen Klasko named Chairman of the Board as part of the Board’s leadership changes.
- Board has engaged Spencer Stuart to lead the search for a permanent Chief Executive Officer.
- Preliminary full-year 2025 revenue guidance revised to $3.270 billion–$3.278 billion (prior: $3.305 billion–$3.320 billion) due to softer demand for intra-aortic balloon pumps and catheters and OEM order delays.
Jan 8, 2026, 11:55 AM
Teleflex Announces Interim CEO and Updates FY2025 Revenue
TFX
CEO Change
Board Change
Guidance Update
- Appointed Stuart Randle as Interim President & CEO and Dr. Stephen Klasko as Chairman; Board has engaged Spencer Stuart to lead the search for a permanent CEO.
- Provided preliminary FY2025 revenue outlook of $3.270 billion to $3.278 billion, down from prior guidance of $3.305 billion to $3.320 billion due to softer demand and order delays.
- Scheduled to report full Q4 and FY2025 results in late February/early March 2026.
Jan 8, 2026, 11:30 AM
Teleflex announces sale of acute care, interventional urology and OEM businesses
TFX
M&A
Share Buyback
- Teleflex entered into definitive agreements to sell its Acute Care and Interventional Urology businesses to Intersurgical Ltd and its OEM business to Montagu and Kohlberg for a combined $2.03 billion in cash, subject to closing adjustments.
- Under the agreements, the company expects to receive approximately $1.5 billion for the OEM business and $530 million for the Acute Care and Interventional Urology businesses, yielding net proceeds of about $1.8 billion after tax.
- The transactions are expected to close in the second half of 2026, subject to customary regulatory approvals and closing conditions.
- Teleflex’s Board has authorized a new $1 billion share repurchase program, to be primarily funded with proceeds from these sales.
Dec 9, 2025, 10:08 PM
Teleflex to sell Medical OEM unit to Montagu and Kohlberg
TFX
M&A
Management Change
- Teleflex agreed to sell its Medical OEM unit to Montagu and Kohlberg for $1.5 billion, with closing expected in H2 2026
- Teleflex Medical OEM is a leading contract developer and manufacturer with seven facilities across the U.S., Mexico, and Ireland
- Upon closing, Greg Stotts will become Chief Executive Officer of the standalone company
- Montagu and Kohlberg will apply their carve-out expertise and healthcare investment track record to drive the unit’s growth
Dec 9, 2025, 2:20 PM
Fintool News
In-depth analysis and coverage of TELEFLEX.
Quarterly earnings call transcripts for TELEFLEX.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more